Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 3 of 30
Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access
NCT06658067
Drinking, Acetate, and Stress
NCT06584448
PRIDE III Prison Interventions and HIV Prevention Collaboration
NCT06962033
Developing a Novel Human Laboratory Paradigm for AUD Medication Screening
NCT06489782
Oral Contraceptive Pill (OCP) Pharmacogenomics
NCT06334315
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
NCT06172660
Combined THC and CBD for OUD and Chronic Pain
NCT06544291
Open-Label Psilocybin Study in Transdiagnostic Population
NCT06442423
MyChart Proxy Outreach to Parents (MyPOP)
NCT05989308
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
NCT05989347
Longitudinal Neural Fingerprinting of Opioid-use Trajectories
NCT06207162
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
NCT05996185
Speech Motor Learning and Retention (Aim 1)
NCT06467305
Speech Motor Learning and Retention (Aim 2)
NCT06491823
Speech Motor Learning and Retention (Master Protocol)
NCT06467292
M2VA Pain Care Pathway
NCT06526143
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
NCT06058702
Imaging Depression in Parkinson's Disease
NCT06402955
Effects of E-cigs vs Pouches on Cigarette Smoking and Addiction
NCT06077240
Emergency Department-Initiated Medications for Alcohol Use Disorder
NCT05827159
Affirmative Family and Individual Psychotherapy for Sexual and Gender Minority Adults and Their Nonaccepting Parents
NCT05766592
Music Mindfulness Study 2a.
NCT06505226
Evaluating the Impact of Social Music
NCT06513910
Adaptation and Implementation of Peer Support in Brazil
NCT05842889
PRISM: Patient Experiences With PET Imaging in Prostate Cancer
NCT06523777
Mechanisms of Diuretic Resistance in Heart Failure, Aim 3
NCT06209359
Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement
NCT05796505
Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)
NCT05776563
Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
NCT06411210
Blood Pressure Variability and Ischemic Stroke Outcome
NCT05756257
Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers
NCT06136195
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging
NCT05907629
Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat
NCT06371404
Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.
NCT06323824
Assessing the Effectiveness of Digital Wellness Modules on Perceived Quality of Life
NCT05810259
Glu-COACH: a Peer-mentoring Intervention to Reduce Disparities in Continuous Glucose Monitor (CGM) Use
NCT06171412
Reestablishing Sleep and Circadian Alignment in Medical Intensive Care Unit (MICU) Patients Via a Mechanistic RCT of an Sleep Chronobundle
NCT05551325
Single Session Intervention to Promote Hope
NCT06375876
Biliary Atresia Research Network Northeast
NCT06184971
Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum Disorder
NCT06142955
Recovery Finance: Financial Health and Mental Health After Incarceration
NCT06914856
Time to BBVNA Relief
NCT07433634
The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
NCT06111781
PRESSURE CHECK: Find Your Path to Better Health
NCT06122246
Modulating Temporoparietal Junction Mentalizing-Related Activity in Autism Spectrum Disorder (ASD) Using Transcranial Magnetic Stimulation (TMS)
NCT06214065
Peru Decentralized HIV Care
NCT05910268
Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use
NCT06027840
Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healthcare Encounters and Quality of Life
NCT06163469
Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study
NCT05612594
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
NCT06375811
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Yale University pipeline card: 1,492 registered trials from official public datasets.Report a data error.